Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20.

Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20.

Item

http://www.wikidata.org/entity/Q34703634

Q34703634

about

Comparison of EndoPredict and Oncotype DX test results in hormone receptor positive invasive breast cancer Targeted therapies with companion diagnostics in the management of breast cancer: current perspectives The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis Validation of biomarkers to predict response to immunotherapy in cancer: Volume II - clinical validation and regulatory considerations Hormonal Modulation of Breast Cancer Gene Expression: Implications for Intrinsic Subtyping in Premenopausal Women Sleep duration and breast cancer phenotype Prospective Validation of a 21-Gene Expression Assay in Breast Cancer Breast cancer classification and prognostication through diverse systems along with recent emerging findings in this respect; the dawn of new perspectives in the clinical applications.Tailored targeted therapy for all: a realistic and worthwhile objective against.Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment.Optimizing the Use of Gene Expression Profiling in Early-Stage Breast Cancer.Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer.Societal cost-effectiveness analysis of the 21-gene assay in estrogen-receptor-positive, lymph-node-negative early-stage breast cancer in Japan.The impact of Oncotype DX testing on breast cancer management and chemotherapy prescribing patterns in a tertiary referral centre.Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 Can molecular subtyping replace axillary nodal status as prognostic marker in breast cancer?Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors.Impact of multigene assays in early stage breast cancer.Molecular characterisation of formalin-fixed paraffin-embedded (FFPE) breast tumour specimens using a custom 512-gene breast cancer bead array-based platform.Translational genomics: the challenge of developing cancer biomarkers.Treatment differences between urban and rural women with hormone receptor-positive early-stage breast cancer based on 21-gene assay recurrence score result.Biomarker development in the context of urologic cancers Toward individualized breast cancer therapy: translating biological concepts to the bedside.Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer.Clinical utility of gene-expression profiling in women with early breast cancer: an overview of systematic reviews.The value of multigene predictors of clinical outcome in breast cancer: an analysis of the evidence Oncotype DX in Bilateral Synchronous Primary Invasive Breast Cancer.Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study Comparative Effectiveness of Biomarkers to Target Cancer Treatment: Modeling Implications for Survival and Costs Breast cancer subtype intertumor heterogeneity: MRI-based features predict results of a genomic assay.Evaluating use characteristics for the oncotype dx 21-gene recurrence score and concordance with chemotherapy use in early-stage breast cancer.How much can improved molecular and pathologic discriminants change local therapy?Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer.21-Gene Recurrence Score Assay As a Predictor of Adjuvant Chemotherapy Administration for Early-Stage Breast Cancer: An Analysis of Use, Therapeutic Implications, and Disparity Profile.Adoption of Gene Expression Profiling for Breast Cancer in US Oncology Practice for Women Younger Than 65 Years.Association Between Phosphorylated Histone H3 and Oncotype DX Recurrence Scores in Breast Cancer.Cost-effectiveness analysis of Mammostrat® compared with Oncotype DX® to inform the treatment of breast cancer.Evaluation and correlation of risk recurrence in early breast cancer assessed by Oncotype DX(®), clinicopathological markers and tumor cell dissemination in the blood and bone marrow.Regional differences in breast cancer biomarkers in american Indian and Alaska native women.Clinical validity/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for early-stage breast cancer: a systematic review.

P2860

Q21089802-6731FE08-6996-462D-8F61-A93D90425DA8 Q26768119-EF1FBF1E-E761-484C-BE3F-A427B8D70B32 Q26861418-F4EE48DF-BC46-4815-96B7-B40405734C00 Q28066738-972F30B3-FC46-49B8-B7BA-E7FB5C44E0DD Q28077637-27ACB1B0-4315-4714-A4DA-8C441A6876E0 Q28391366-4FCE4906-2292-49BE-8C69-DEEF5DA57FF3 Q29011698-CF2C222E-7828-43AE-80A2-B86CEDF24B6C Q30245184-955AE215-ED25-4262-B73D-F738BE86ACF0 Q33555480-0A61C8EE-2EB6-4DAC-9228-7BAB8303C670 Q33698446-D17C74EC-D12F-42CA-BFC1-F474EAB3A159 Q33756398-297A6274-BA6C-4E92-B492-1AF9CB84066A Q33766513-96AC2FFB-1ABB-45BB-B847-1F53EC8C5571 Q34196301-8DF55EBC-70B7-44E1-9E86-C7248E129C70 Q34376320-9D29A9B0-F3ED-4255-96CB-09EF1BA8C019 Q35130819-1D9FD161-D24C-4675-9FCC-97D0D6446882 Q35162833-6DC59295-F36C-4602-95BD-3AF442E93D4F Q35565641-7755C482-35AC-4363-9C98-C863FD3C0805 Q35599759-201466CD-9156-4D06-ADBE-E6A62E821094 Q35623047-EA3EBB6B-4EA9-485C-B080-A72459FF640E Q35694362-5FD01F3B-D55F-486B-91B7-9B7F825A22F7 Q35879597-A16D2E74-1C3E-429F-B7C0-A5EA498DE800 Q35906352-E98FAA7E-76EB-44A4-AE2B-1982FF1BA60F Q35913199-EADED838-82BE-463C-A4C5-AAC257552CE1 Q35998425-08E2A957-3D9B-44C3-9595-E5F631E376C3 Q36424052-06C17F57-ED9C-46B6-939E-CAC9A8CA3A05 Q36462893-BBB6B1DE-2057-4573-93E5-4F615002DBA7 Q36483940-DD65406B-79D9-4E45-95B4-ED5204340376 Q36554725-EA248728-63AE-407D-8D30-39DE08532E95 Q36614650-D55D2ECB-C766-4516-BF62-FC2B59BD2BB1 Q36668293-C6F2048F-586D-438E-86D1-78E329A368AC Q37008507-31D2DCDD-7115-4DAC-AA27-6218169EEE61 Q37039849-4A61CE3E-D0FF-4435-BFDF-27F2083D20C5 Q37095310-CCAFB5F1-6F79-4BFF-986E-32226C808851 Q37138266-9E2D21E3-F414-49C4-847F-201241BB7A9A Q37151779-D282BD2B-C0F2-41D8-9B72-49F17BBF74DC Q37488438-A3C00837-B099-49C9-BEE0-5BD265D3E622 Q37495490-E5433900-4638-4BCE-93FC-6E88E631712C Q37560700-AD3FCDBD-7E34-46BC-A8DE-D594710C09FE Q37638649-1A92E5CD-4110-45D4-82AD-FBFFFE0E5621 Q38024305-2CB40D2D-FD44-458F-9A0B-7FE70E6346CE

P2860

Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20.

Item

http://www.wikidata.org/entity/Q34703634

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu